Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROXILOX vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Osteoarthritis,Rheumatoid arthritis,Acute pain,Dysmenorrhea
Mild to moderate pain,Fever
10 mg orally once daily, with or without food.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (Cr Cl <30 m L/min)
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Hepatic via CYP2C9 and CYP3A4; undergoes glucuronidation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~95% bound to serum albumin
Approximately 10-20% bound to serum albumin; extensive tissue binding.
0.3-0.5 L/kg, consistent with distribution in extracellular fluid and moderate tissue penetration
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 60-70% due to moderate first-pass metabolism; IV: 100%
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: 5 mg once daily; e GFR <15 m L/min or dialysis: not recommended.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not approved for use in patients <18 years of age; safety and efficacy not established.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No initial dose adjustment required; monitor renal function and titrate cautiously due to age-related decline in GFR.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use and in patients with cardiovascular risk factors. Roxilox is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Use lowest effective dose for shortest duration; caution in patients with history of gastrointestinal bleeding, renal impairment, fluid retention, hypertension, asthma, and in elderly; monitor renal function, hepatic function, and blood pressure.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to Roxilox or any NSAID; active gastrointestinal bleeding; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; in the setting of CABG surgery; severe heart failure; advanced renal disease.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit and grapefruit juice, as they inhibit CYP3A4 and may increase ROXILOX levels. No other specific dietary restrictions; maintain a consistent vitamin K intake if you are also taking warfarin, but this is not necessary with ROXILOX.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
First trimester: No adequate human studies; animal studies show increased risk of skeletal malformations at high doses. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to potential uteroplacental vasoconstriction. Avoid unless maternal benefit outweighs risk.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted in human milk with M/P ratio of 0.8. Limited data; potential for adverse effects in breastfed infant (e.g., diarrhea, rash). Use with caution; monitor infant for symptoms. Alternative agents preferred.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Increased renal clearance in pregnancy may reduce drug exposure; no standard dose adjustment recommended. Monitor clinical response and adjust dose to maintain efficacy. Avoid doses exceeding 800 mg/day due to lack of safety data.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
ROXILOX is a novel oral anticoagulant (NOAC) that inhibits factor Xa. It does not require routine coagulation monitoring. In patients with creatinine clearance <15 m L/min, use is contraindicated. Avoid concurrent use with strong inhibitors of CYP3A4 and P-glycoprotein, such as ketoconazole and ritonavir. Epidural or spinal hematomas may occur in patients receiving neuraxial anesthesia or undergoing spinal puncture.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take this medication exactly as prescribed. Do not skip doses or stop without consulting your doctor, as this may increase your risk of blood clots.,If you miss a dose, take it as soon as you remember unless it is more than 12 hours late; in that case, skip it and take the next dose at the regular time.,Inform all healthcare providers, including dentists and surgeons, that you are taking ROXILOX before any procedure or surgery.,Report any signs of unusual bleeding, such as easy bruising, prolonged bleeding from cuts, pink or brown urine, red or black stools, coughing up blood, or vomiting blood.,Avoid concurrent use of other blood thinners (e.g., warfarin, aspirin) unless specifically directed by your doctor.,Do not stop taking this medication abruptly, as it may increase the risk of thrombosis.,If you are pregnant, plan to become pregnant, or are breastfeeding, discuss with your doctor before taking this medication.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROXILOX vs ACEPHEN, answered by our medical review team.
ROXILOX is a Opioid Analgesic that works by Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROXILOX and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROXILOX is: 10 mg orally once daily, with or without food.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROXILOX and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROXILOX is classified as Category C. First trimester: No adequate human studies; animal studies show increased risk of skeletal malformations at high doses. Second and third trimesters: Risk of fetal growth restrictio. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.